Erlotinib vs Gefitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Erlotinib

Rights held by Cheplapharm Arzneimittel GmbH and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00446225 · Phase 3 · completed

EURTAC was a randomized, open-label Phase 3 in 174 patients with EGFR-mutant advanced NSCLC comparing erlotinib with platinum-based chemotherapy. Its primary endpoint, progression-free survival, is a clinical outcome and was met (HR 0.42). An open-label trial is never graded strong under the rubric.

Next expected readout: December 2027 · NCT04449874 (registry estimate)

Reported efficacy

Progression Free-survival (From the date of randomization to the date of last follow up, assessed up to 24 months): Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results). (met)

Result source: NCT00446225

Gefitinib

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00020709 · Phase 3 · completed

SWOG S0023 registered 840 patients for chemoradiation and docetaxel consolidation; 243 of them were then randomized, double-blind, to gefitinib or placebo maintenance. The primary endpoint, overall survival, is a hard clinical outcome. An unplanned interim analysis stopped the randomized comparison, and survival was shorter with gefitinib than with placebo. The key result shown was recovered from the cited publication.

Next expected readout: July 2027 · NCT03333343 (registry estimate)

Reported efficacy

Overall Survival (From date of registration to date of death due to any cause, assessed up to 10 years); Progression-free survival (From date of registration to date of first observation of progressive disease, death due to any cause, assessed up to 10 years): Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 (missed)

Result source: NCT00020709

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointErlotinibGefitinib
PFS, median7.6 vs 6+1.6 vs placebon 226NCT00883779
7 other results
5.4 vs 5.4±0 vs placebon 133NCT01544179
14 other results
OS, median11.9 vs 10.2vs Standard of Caren 245NCT01351415
11 other results
14.8 vs 17.2−2.4 vs placebon 133NCT01544179
8 other results
ORR42.9% vs 17.8%+25.1 vs placebon 226NCT00883779
23 other results
31.6% vs 34.1%−2.5 vs placebon 133NCT01544179
5 other results
  • 55% vs 28.6% n 60 · Phase 1/2 · primary NCT02039674
  • 29.5% n 44 · Phase 1/2 · primary NCT02039674
  • 45.2% vs 33.3% 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
Duration of response, median10.3 vs 5.6+4.7 vs placebon 97NCT00883779
3 other results
—Not posted · NCT03653546

PFS, median

Erlotinib
7.6 vs 6+1.6 vs placebon 226NCT00883779
7 other results
Gefitinib
5.4 vs 5.4±0 vs placebon 133NCT01544179
14 other results

OS, median

Erlotinib
11.9 vs 10.2vs Standard of Caren 245NCT01351415
11 other results
Gefitinib
14.8 vs 17.2−2.4 vs placebon 133NCT01544179
8 other results

ORR

Erlotinib
42.9% vs 17.8%+25.1 vs placebon 226NCT00883779
23 other results
Gefitinib
31.6% vs 34.1%−2.5 vs placebon 133NCT01544179
5 other results
  • 55% vs 28.6% n 60 · Phase 1/2 · primary NCT02039674
  • 29.5% n 44 · Phase 1/2 · primary NCT02039674
  • 45.2% vs 33.3% 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955

Duration of response, median

Erlotinib
10.3 vs 5.6+4.7 vs placebon 97NCT00883779
3 other results
Gefitinib
—Not posted · NCT03653546
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Erlotinib: 10 of 10 rows · Gefitinib: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricErlotinib
Rows use multiple source trials
Gefitinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
80.2% (n=245) vs 77% (n=240) Standard of Carea,b,c
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
4 other source trials
67.3% (n=226) vs 64.4% (n=225) placebo
NCT00883779 · Phase 3 · registry result, not featured evidence
64.5% (n=76) vs 53.8% (n=78) placebo @ 16wk
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
73% (n=63) vs 85.2% (n=61) Bevacizumab + Chemotherapy
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
85.7% (n=7) vs 50% (n=8) Gemcitabine
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
84.2% (n=133) vs 78.8% (n=132) placeboa,b,c
NCT01544179 · Phase 3 · registry result, not featured evidence
1 other source trial
83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
12.5% (n=24)d,e,a,c
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
62.7% (n=67)
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
29.5% (n=44)e,a,c
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
2 other source trials
33.3% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
33.3% (n=12)500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
6.08 monthsd,f,a,c
NCT00550537 · Phase 2 · registry result, not featured evidence
show 2 more doses
12.53 months
NCT00550537 · Phase 2 · registry result, not featured evidence · combination
17.23 months
NCT00550537 · Phase 2 · registry result, not featured evidence · combination
19.22 monthsf,a,c
NCT01203917 · Phase 4 · registry result, not featured evidence
2 other source trials
10.22 months*
NCT01530334 · Phase 2 · registry result, not featured evidence · converted to months from 311 days as posted
10 months
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
6.3 monthsd,f,a,b,c
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
6.7 months
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
9.72 monthsd,f,a,b,c
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more dose
6.97 months
NCT01203917 · Phase 4 · registry result, not featured evidence
Time to Progression
time to event · months
7.9 vs 6.5 placebo monthsg,a,b,c
NCT00883779 · Phase 3 · registry result, not featured evidence
1 other source trial
7.25 vs 5.56 placebo months*
NCT01998919 · Phase 2 · registry result, not featured evidence · combination · converted to months from 31.4 weeks as posted
19.48 vs 10.81 Gefitinib monthsg,a,b,c
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Symptomatic Progression
time to event · months
7.2 vs 6.6 placebo monthsh,a,b,c
NCT00883779 · Phase 3 · registry result, not featured evidence
5.75 vs 7.95 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mgh,a,b,c
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestonei
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
38.1%
NCT00883779 · Phase 3 · registry result, not featured evidence
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
5.5%
NCT00621049 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneBevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneBevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
47.3%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
78.9%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
7.1%Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
14.3%Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
5.8%Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
8.3%Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
12.9%Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
17.5%Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
10.5%Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
7.7%Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
40.6%i
NCT00322452 · Phase 3
show 40 more results
—250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
33.6%Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
54.7%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
9.6%
NCT00608868 · Phase 4 · registry result, not featured evidence
—250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
47.4%Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
0.8%
NCT00049543 · Phase 3 · registry result, not featured evidence
62.3%
NCT02856893 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
83.6%
NCT01530334 · Phase 2 · registry result, not featured evidence
0%
NCT00824746 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT00264498 · Phase 2 · registry result, not featured evidence
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
7.7%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—i
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
7.1%
NCT00883779 · Phase 3 · registry result, not featured evidence
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
—
NCT00621049 · Phase 2 · registry result, not featured evidence
25%Bevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
10.4%Bevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
6.8%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
—
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
37.5%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
3%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—i
NCT00322452 · Phase 3
show 40 more results
—250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
—Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
6.1%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
0.6%
NCT00608868 · Phase 4 · registry result, not featured evidence
—250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
0%Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
—
NCT00049543 · Phase 3 · registry result, not featured evidence
3.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
4.9%
NCT01530334 · Phase 2 · registry result, not featured evidence
—
NCT00824746 · Phase 2 · registry result, not featured evidence
—
NCT00264498 · Phase 2 · registry result, not featured evidence
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
3%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
51.9%i
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
31%
NCT00883779 · Phase 3 · registry result, not featured evidence
23.4%
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
25.5%
NCT00621049 · Phase 2 · registry result, not featured evidence
29.2%Bevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
40.3%Bevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
23%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
10.5%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
27%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
75%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
25%200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
61.5%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
50%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
36.4%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
66.7%Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
58.6%Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
25%Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
52.4%Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
44.2%Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
66.7%Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
80%Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
55.6%Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
75%Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
33.3%Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
38.7%Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
52.5%Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
65.8%Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
64.1%Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
18.1%i
NCT00322452 · Phase 3
show 40 more results
19.6%250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
—Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
6.8%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
16.2%
NCT00608868 · Phase 4 · registry result, not featured evidence
28.8%250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
—Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
13.7%
NCT00049543 · Phase 3 · registry result, not featured evidence
17%
NCT02856893 · Phase 2 · registry result, not featured evidence
42.9%800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
60%600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
22.6%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
40.4%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
37.5%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
28.6%200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
71.4%200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
20%100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
17.2%
NCT01530334 · Phase 2 · registry result, not featured evidence
—
NCT00824746 · Phase 2 · registry result, not featured evidence
—
NCT00264498 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
61.5%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
50%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
36.4%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
41.9%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
66.7%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
41.7%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
i
diarrhoea 37%
nausea 34.6%
decreased appetite 34.2%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 38 more results
rash 62.8% (placebo 32.4%)
neutropenia 50.4% (placebo 49.5%)
nausea 39.8% (placebo 41.4%)
NCT00883779 · Phase 3 · registry result, not featured evidence
rash 55.4% (placebo 18.8%)
diarrhoea 51.1% (placebo 19.6%)
fatigue 34.2% (placebo 24.8%)
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
fatigue 67.3%
nausea 58.2%
diarrhea 47.3%
NCT00621049 · Phase 2 · registry result, not featured evidence
asthenia 62.5%
diarrhoea 62.5%
folliculitis 45.8%
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
asthenia 71.6%
hypertension 52.2%
neutropenia 49.3%
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
rash 64.9% (placebo 40.5%)
nausea 45.9% (placebo 46.8%)
decreased appetite 40.5% (placebo 41.8%)
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
anaemia of malignant disease 36.8%
thrombocytopenia 31.6%
rash 15.8%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
rash 61.9%
diarrhoea 42.9%
cough 30.2%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
rash 87.5%
diarrhoea 75%
anorexia 62.5%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
200 mg
decreased appetite 32.1% (placebo 27.4%)
fatigue 25% (placebo 58.1%)
cough 21.4% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
nausea 72.9% (placebo 59.7%)
fatigue 69.5% (placebo 58.1%)
constipation 54.2% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
alopecia 61.5% (placebo 3.2%)
cough 53.8% (placebo 27.4%)
decreased appetite 53.8% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 91.7% (placebo 58.1%)
constipation 58.3% (placebo 40.3%)
anaemia 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100% (placebo 58.1%)
actinic keratosis 33.3% (placebo 1.6%)
back pain 33.3% (placebo 12.9%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
arthralgia 66.7% (placebo 29%)
chills 66.7% (placebo 4.8%)
cough 66.7% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 61.5% (placebo 40.3%)
fatigue 61.5% (placebo 58.1%)
alopecia 53.8% (placebo 3.2%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 81.8% (placebo 40.3%)
alopecia 72.7% (placebo 3.2%)
fatigue 72.7% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 66.7% (placebo 40.3%)
nausea 58.3% (placebo 59.7%)
fatigue 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 41.7% (placebo 40.3%)
vomiting 41.7% (placebo 32.3%)
cough 33.3% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 66.7% (placebo 30.6%)
fatigue 58.3% (placebo 58.1%)
cough 50% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 57.1% (placebo 30.6%)
pruritus 42.9% (placebo 11.3%)
rash 28.6% (placebo 16.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 48.5% (placebo 58.1%)
constipation 27.3% (placebo 40.3%)
arthralgia 24.2% (placebo 29%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.7% (placebo 58.1%)
alopecia 58.3% (placebo 3.2%)
constipation 58.3% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 83.3%
fatigue 83.3%
anaemia 66.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 93.3%
nausea 80%
decreased appetite 60%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 79.3%
alopecia 51.7%
constipation 51.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
cough 58.3%
fatigue 50%
dyspnoea 41.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 76.2%
rash 61.9%
diarrhoea 47.6%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
cough 53.8%
fatigue 53.8%
constipation 32.7%
NCT01454102 · Phase 1 · registry result, not featured evidence
decreased appetite 66.7%
diarrhoea 44.4%
fatigue 44.4%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 73.3%
diarrhoea 66.7%
cough 40%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 66.7%
cough 33.3%
decreased appetite 33.3%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 68.8%
decreased appetite 50%
nausea 50%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 58.3%
cough 41.7%
constipation 25%
NCT01454102 · Phase 1 · registry result, not featured evidence
fatigue 51.6%
dyspnoea 41.9%
cough 35.5%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
rash 35%
diarrhoea 32.5%
fatigue 32.5%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
pruritus 42.1%
fatigue 36.8%
cough 34.2%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 46.2%
decreased appetite 35.9%
cough 33.3%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
i
rash 50.7%
diarrhoea 45%
dry skin 23.7%
NCT00322452 · Phase 3
show 37 more results
250 mg
rash 46.7%
diarrhoea 29%
asthenia 11.2%
NCT01203917 · Phase 4 · registry result, not featured evidence
250 mg
rash 49.7% (placebo 9.5%)
serious hepatic dysfunction 29.3% (placebo 10.8%)
diarrhoea 25.2% (placebo 8.8%)
NCT00770588 · Phase 4 · registry result, not featured evidence
rash 33.8%
diarrhoea 26%
pruritus 17.5%
NCT00608868 · Phase 4 · registry result, not featured evidence
250 mg
nausea 63.6% (placebo 60.6%)
decreased appetite 48.5% (placebo 34.1%)
vomiting 40.9% (placebo 32.6%)
NCT01544179 · Phase 3 · registry result, not featured evidence
rash 67.1% (placebo 27.2%)
diarrhea 62.2% (placebo 30.9%)
fatigue 54.2% (placebo 53.5%)
NCT00049543 · Phase 3 · registry result, not featured evidence
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
800 mg Cap QD
vomiting 100%
nausea 85.7%
decreased appetite 57.1%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
600 mg Cap BID
cough 60%
decreased appetite 60%
hypoproteinaemia 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 43.4%
anaemia 34%
oedema peripheral 28.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 58.3%
blood bilirubin increased 41.7%
amylase increased 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap QD
nausea 50%
cough 33.3%
oedema peripheral 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
nausea 55.3%
oedema peripheral 44.7%
decreased appetite 40.4%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
decreased appetite 37.5%
diarrhoea 37.5%
headache 37.5%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap BID
diarrhoea 75%
hypoalbuminaemia 75%
anaemia 50%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap QD
back pain 57.1%
rash 42.9%
vomiting 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Tab BID
nausea 71.4%
dermatitis acneiform 57.1%
cystitis 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
100 mg Cap QD
constipation 60%
pruritus 60%
amylase increased 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
diarrohea 27.6%
rash 15.5%
vomiting 15.5%
NCT01530334 · Phase 2 · registry result, not featured evidence
diarrhoea 53.8%
dyspnoea 34.6%
nausea 30.8%
NCT00264498 · Phase 2 · registry result, not featured evidence
200 mg
decreased appetite 32.1% (placebo 27.4%)
fatigue 25% (placebo 58.1%)
cough 21.4% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
nausea 72.9% (placebo 59.7%)
fatigue 69.5% (placebo 58.1%)
constipation 54.2% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
alopecia 61.5% (placebo 3.2%)
cough 53.8% (placebo 27.4%)
decreased appetite 53.8% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 91.7% (placebo 58.1%)
constipation 58.3% (placebo 40.3%)
anaemia 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100% (placebo 58.1%)
actinic keratosis 33.3% (placebo 1.6%)
back pain 33.3% (placebo 12.9%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
arthralgia 66.7% (placebo 29%)
chills 66.7% (placebo 4.8%)
cough 66.7% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 61.5% (placebo 40.3%)
fatigue 61.5% (placebo 58.1%)
alopecia 53.8% (placebo 3.2%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 81.8% (placebo 40.3%)
alopecia 72.7% (placebo 3.2%)
fatigue 72.7% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 66.7% (placebo 40.3%)
nausea 58.3% (placebo 59.7%)
fatigue 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 41.7% (placebo 40.3%)
vomiting 41.7% (placebo 32.3%)
cough 33.3% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 66.7% (placebo 30.6%)
fatigue 58.3% (placebo 58.1%)
cough 50% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 57.1% (placebo 30.6%)
pruritus 42.9% (placebo 11.3%)
rash 28.6% (placebo 16.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 48.5% (placebo 58.1%)
constipation 27.3% (placebo 40.3%)
arthralgia 24.2% (placebo 29%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.7% (placebo 58.1%)
alopecia 58.3% (placebo 3.2%)
constipation 58.3% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
500 mg + 250 mg
diarrhoea 83.3%
dyspnoea exertional 41.7%
fatigue 41.7%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
500 mg + 250 mg
diarrhoea 58.1%
oedema peripheral 38.7%
amylase increased 35.5%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
300 mg + 250 mg
amylase increased 66.7%
diarrhoea 66.7%
blood alkaline phosphatase increased 50%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
diarrhea 41.7%
dysphagia 33.3%
rash 33.3%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 1/2.
  6. fTrial phases differ: Phase 2 versus Phase 4.
  7. gTrial phases differ: Phase 3 versus Phase 2.
  8. hTrial phases differ: Phase 3 versus Phase 1/2.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Erlotinib

PFS2 5.45 vs 3.98 Standard of Care months
time to event · months
PFS 2
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 0.8% (n=245) vs 0.7% (n=240) Standard of Care @ 26wk
responder rate · % of participants
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
0.5% (n=245) vs 0.4% (n=240) Standard of Care @ 52wk
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
0.4% (n=245) vs 0.3% (n=240) Standard of Care @ 78wk
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
PFS 22.6% (n=226) vs 6.2% (n=225) placebo
responder rate · % of participants
NCT00883779 · Phase 3 · registry result, not featured evidence
Overall Survival 18.2 vs 15.2 placebo months
time to event · months
Overall participants (n=225,226)
NCT00883779 · Phase 3 · registry result, not featured evidence
Overall Survival 15.9% (n=226) vs 13.3% (n=225) placebo
responder rate · % of participants
Overall participants (n=225,226)
NCT00883779 · Phase 3 · registry result, not featured evidence
Symptomatic Progression 66.4% (n=226) vs 72.4% (n=225) placebo
responder rate · % of participants
NCT00883779 · Phase 3 · registry result, not featured evidence
FACT TOI Deterioration 65.9% (n=226) vs 75.6% (n=225) placebo
ratio to baseline · % of baseline
NCT00883779 · Phase 3 · registry result, not featured evidence
Time to Deterioration FACT TOI 6.3 vs 5.6 placebo months
time to event · months
NCT00883779 · Phase 3 · registry result, not featured evidence
FACT-L Deterioration 70.4% (n=226) vs 79.6% (n=225) placebo
ratio to baseline · % of baseline
NCT00883779 · Phase 3 · registry result, not featured evidence
Time to Deterioration FACT 5.6 vs 4.5 placebo months
time to event · months
NCT00883779 · Phase 3 · registry result, not featured evidence
Disease-free Survival NA vs 55.1 Docetaxel and Carboplatin months
time to event · months
NCT00621049 · Phase 2 · registry result, not featured evidence
Overall Survival Rate at 24 78.2% (n=55) vs 71.9% (n=57) Docetaxel and Carboplatin @ 104wk
responder rate · % of participants
NCT00621049 · Phase 2 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

Gefitinib

ORR 23.6% (n=148) vs 0.7% (n=148) placebo250 mg
event count · % of participants
NCT00770588 · Phase 4 · registry result, not featured evidence · converted to % from 35 Participants as posted
show 1 more result
43% (n=609) vs 32.2% (n=608) Carboplatin/Paclitaxel*
NCT00322452 · Phase 3 · converted to % from 262 Participants as posted
ORR 69.8% (n=106)
responder rate · % of participants
No placebo or comparator arm
% Responders
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more result
50% (n=106)
% Responders
NCT01203917 · Phase 4 · registry result, not featured evidence
Disease Control 90.6% (n=106)
responder rate · % of participants
No placebo or comparator arm
% Controlled
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more result
88.7% (n=106)
% Controlled
NCT01203917 · Phase 4 · registry result, not featured evidence
ORR 31.2% (n=138)
absolute value · percentage points
No placebo or comparator arm
NCT00608868 · Phase 4 · registry result, not featured evidence
FACT-L Improvement 41% (n=94)
responder rate · % of participants
No placebo or comparator arm
NCT00608868 · Phase 4 · registry result, not featured evidence
Overall Survival 0.52% (n=251) vs 0.57% (n=252) placebo @ 260wk
absolute value · percentage points
NCT00049543 · Phase 3 · registry result, not featured evidence
Disease-free Survival 0.49% (n=251) vs 0.56% (n=252) placebo @ 260wk
absolute value · percentage points
NCT00049543 · Phase 3 · registry result, not featured evidence
PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS2 25.76 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 4.9% (n=61)
event count · % of participants
No placebo or comparator arm
NCT01530334 · Phase 2 · registry result, not featured evidence · converted to % from 3 Patients as posted

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Erlotinib's landscape · Gefitinib's landscape